---
title: "Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights | RVPH Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280996019.md"
description: "Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights | RVPH Stock News"
datetime: "2026-03-30T02:05:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280996019.md)
  - [en](https://longbridge.com/en/news/280996019.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280996019.md)
---

# Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights | RVPH Stock News

Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights | RVPH Stock News

### Related Stocks

- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [RVPH.US](https://longbridge.com/en/quote/RVPH.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)

## Related News & Research

- [Reviva Pharmaceuticals Q1 net loss narrows on lower expenses](https://longbridge.com/en/news/286314912.md)
- [Precigen Q1 revenue beats estimates on PAPZIMEOS launch](https://longbridge.com/en/news/286311056.md)
- [Genprex data shows gene therapy reverses hyperglycemia in T2D mice at ASGCT](https://longbridge.com/en/news/286414681.md)
- [Regenxbio's muscle disorder therapy meets main goal in late-stage study](https://longbridge.com/en/news/286406339.md)
- [Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential](https://longbridge.com/en/news/286284525.md)